List of Excipients in Branded Drug FARYDAK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	FARYDAK	panobinostat	0078-0650	CELLULOSE, MICROCRYSTALLINE	2028-01-17
Novartis Pharmaceuticals Corporation	FARYDAK	panobinostat	0078-0650	MAGNESIUM STEARATE	2028-01-17
Novartis Pharmaceuticals Corporation	FARYDAK	panobinostat	0078-0650	MANNITOL	2028-01-17
Novartis Pharmaceuticals Corporation	FARYDAK	panobinostat	0078-0650	STARCH, CORN	2028-01-17
Secura Bio Inc	FARYDAK	panobinostat	73116-100	CELLULOSE, MICROCRYSTALLINE	2028-01-17
Secura Bio Inc	FARYDAK	panobinostat	73116-100	FD&C BLUE NO. 1	2028-01-17

Farydak Excipient Strategy and Commercial Opportunities in Panobinostat Capsules

Last updated: August 4, 2026

Farydak (panobinostat) is an oral histone deacetylase inhibitor marketed by Novartis for multiple myeloma in combination with bortezomib and dexamethasone. Its commercial opportunity is concentrated in differentiated oral solid-dose products rather than a simple capsule copy. The most viable excipient strategies are lactose-free formulations, improved gastrointestinal tolerability, alternative capsule shells, modified-release delivery, and lower-cost generic manufacturing.

What is Farydak and how is it formulated?

Farydak contains panobinostat lactate, equivalent to 10 mg, 15 mg, or 20 mg of panobinostat per hard gelatin capsule. The capsules are administered on an intermittent schedule because gastrointestinal toxicity, thrombocytopenia, fatigue, and cardiac risk limit continuous exposure. The U.S. prescribing information identifies the product as an immediate-release oral capsule supplied in three strengths.[1]

Farydak formulation profile

Attribute	Publicly reported information
Active ingredient	Panobinostat lactate
Active moiety	Panobinostat
Drug class	Histone deacetylase inhibitor
Dosage form	Hard gelatin capsule
Strengths	10 mg, 15 mg, 20 mg
Route	Oral
Release profile	Immediate release
Approved combination	Bortezomib and dexamethasone
Disease area	Multiple myeloma
U.S. approval	Feb. 23, 2015
Reference sponsor	Novartis Pharmaceuticals
U.S. NDA	205353

The U.S. label identifies lactose monohydrate, pregelatinized starch, talc, and magnesium stearate among the capsule-fill excipients. The capsule shell contains gelatin, titanium dioxide, and colorants that differ by strength.[1]

The formulation is conventional. It does not appear to rely on a proprietary lipid carrier, polymeric dispersion, enteric coating, osmotic system, or complex multiparticulate architecture. That simplicity lowers manufacturing barriers for generic developers but creates room for differentiated products that address tolerability, excipient sensitivity, supply cost, or administration convenience.

What excipients are used in Farydak capsules?

The core excipient system performs standard functions: lactose provides bulk, pregelatinized starch supports powder flow and capsule fill, talc improves processing, and magnesium stearate provides lubrication.

Excipient functions and commercial implications

Excipient or component	Primary function	Commercial implication
Lactose monohydrate	Diluent and bulk carrier	Creates an opportunity for lactose-free products
Pregelatinized starch	Filler, binder, and disintegration aid	May be replaced by microcrystalline cellulose or co-processed excipients
Talc	Glidant and anti-adherent	Can be reduced or removed in a reformulated process
Magnesium stearate	Lubricant	Requires control of blending time and dissolution impact
Gelatin	Capsule shell	Creates vegetarian, halal, kosher, and non-animal shell opportunities
Titanium dioxide and iron oxides	Opacifier and colorants	Can be replaced to meet regional or customer preferences

The most commercially relevant issue is lactose exposure. Lactose is common in oral solid-dose products and usually does not create a barrier for most patients. It can, however, complicate positioning for patients with lactose intolerance, excipient avoidance preferences, or institutional formularies that favor lactose-free products.

A generic applicant could replace the reference excipient system if the finished product demonstrates pharmaceutical equivalence, bioequivalence, acceptable dissolution, stability, and quality under the applicable FDA pathway. The replacement would not need to replicate the exact inactive ingredients.

What excipient strategies could differentiate a Farydak generic?

1. Lactose-free capsule formulation

A lactose-free version is the clearest low-complexity opportunity. Possible diluent systems include microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch derivatives, or co-processed filler-binders.

The commercial value is moderate rather than transformational. A lactose-free capsule could support specialty-pharmacy differentiation, hospital procurement, and international markets with stronger excipient-labeling preferences. The formulation must preserve the dissolution profile of the low-dose 10 mg capsule, where small changes in fill composition can have a disproportionate effect on content uniformity and release.

2. Gelatin-free capsule shell

A hard hypromellose capsule could replace gelatin. This may support vegetarian, halal, kosher, or non-animal product positioning. Hypromellose shells also offer supply-chain diversification and may simplify access to certain markets.

The regulatory burden is manageable, but the shell change is not trivial. Developers must evaluate moisture transmission, shell brittleness, fill-shell interaction, stability, colorant compatibility, and packaging performance. Because panobinostat is administered in a high-risk oncology population, a shell change would need to be supported by robust stability and bioequivalence data rather than marketing claims alone.

3. Improved powder-flow and low-shear manufacturing

Farydak capsules contain low milligram quantities of active drug relative to the total capsule fill. This creates a content-uniformity challenge, particularly for the 10 mg strength. A co-processed excipient system could improve:

• Blend uniformity
• Flow through capsule-filling equipment
• Reduction of segregation
• Scale-up reproducibility
• Yield and manufacturing cost

This is a practical opportunity for excipient suppliers. The strongest candidates are multifunctional filler-binders and flow-enhancing systems that reduce the need for separate lactose, starch, talc, and lubricant components.

4. Reduced-magnesium-stearate formulation

Magnesium stearate is inexpensive and widely accepted, but over-lubrication can slow wetting and dissolution. A reformulated product could use lower lubricant levels or alternative lubricants such as sodium stearyl fumarate or stearic acid.

The opportunity is primarily manufacturing-related. A reduced-lubricant process may improve dissolution robustness and reduce sensitivity to blending time. It is unlikely to command a major price premium without a measurable clinical or usability benefit.

5. Modified-release or exposure-smoothing formulation

Panobinostat’s toxicity profile creates a stronger rationale for modified release than exists for many oncology capsules. A controlled-release formulation could attempt to reduce peak plasma concentrations, smooth exposure, or reduce gastrointestinal adverse events.

This is a higher-value but higher-risk strategy. A modified-release product would likely require a 505(b)(2) application or another regulatory route involving substantial clinical bridging. It could also trigger new formulation, method-of-use, and device-related patent claims. The product would need to show that altered exposure improves safety or adherence without reducing antimyeloma activity.

6. Sprinkle, sachet, or liquid-compatible dosage form

A capsule that can be opened and sprinkled onto soft food could address swallowing difficulty in older patients and patients with treatment-related fatigue or mucositis. A liquid or powder-for-reconstitution product would expand administration options but creates major stability, taste, dose-uniformity, occupational-handling, and packaging requirements.

Panobinostat is a cytotoxic or hazardous drug under applicable occupational-handling frameworks. Any open-capsule or liquid product would need strong controls for caregiver and pharmacy exposure. This reduces the near-term attractiveness of a simple sprinkle product.

What formulation patents could protect a Farydak follow-on product?

A reformulated panobinostat product could obtain protection around the formulation rather than the active compound. Potential claim categories include:

• Lactose-free capsule compositions
• Specific filler-binder ratios
• Modified-release matrices
• Multiparticulate or pellet systems
• Capsule-shell compositions
• Stabilized panobinostat compositions
• Low-dose content-uniformity processes
• Packaging systems that control moisture or light
• Methods for reducing gastrointestinal toxicity through altered release
• Combination products containing panobinostat, bortezomib, or dexamethasone

The commercial strength of a formulation patent depends on whether the claim requires a narrow excipient combination or covers a clinically meaningful performance attribute. A claim limited to a routine substitution of lactose with microcrystalline cellulose may be vulnerable to obviousness arguments. A claim tied to unexpected dissolution, improved stability, reduced peak exposure, or improved tolerability is stronger.

Manufacturing patents may be more valuable than composition patents if they cover a reproducible low-dose blending process that is difficult to design around. Their value is highest where the process produces measurable quality advantages and is detectable through batch records or product testing.

When does Farydak lose exclusivity and what is the generic-entry risk?

Farydak received FDA approval in 2015 under the accelerated approval pathway for patients with multiple myeloma who had received at least two prior regimens, including bortezomib and an immunomodulatory agent.[2] FDA later converted the indication to traditional approval after confirmatory evidence supported clinical benefit.[3]

The key commercial issue is not only the expiry of active-ingredient patents. Generic entry depends on:

1. FDA Orange Book-listed patents.
2. Regulatory exclusivity.
3. Paragraph IV challenges.
4. Any patent litigation filed after an ANDA notice.
5. Settlement terms between Novartis and generic applicants.
6. The commercial attractiveness of a small, specialty oncology market.

An ANDA applicant may challenge listed patents with a Paragraph IV certification. If the patent holder files suit within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[4]

A generic capsule is likely to face a narrower barrier than a new modified-release product. The standard ANDA pathway can support an immediate-release capsule with different inactive ingredients if the product meets equivalence requirements. A modified-release, sprinkle, or liquid product would likely require a different regulatory strategy and could face additional clinical and patent barriers.

Generic launch scenarios

Scenario	Product concept	Regulatory pathway	Commercial risk
Basic generic	Immediate-release hard capsule	ANDA	Lowest development complexity
Differentiated generic	Lactose-free capsule	ANDA, with formulation bridging	Moderate
Specialty generic	Gelatin-free capsule	ANDA	Moderate
Reformulation	Modified-release capsule	Likely 505(b)(2)	High
Administration innovation	Sprinkle or liquid product	Likely 505(b)(2) or complex ANDA	High
Combination product	Panobinostat with companion agents	New regulatory and IP analysis	High

Exact patent expiry dates and current Orange Book listings should be determined from the live FDA Orange Book and USPTO records before a launch decision. Patent term can differ because of patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and litigation outcomes.

What is the FDA regulatory status of Farydak?

Farydak is an FDA-approved prescription oncology product. The approved U.S. regimen uses intermittent dosing, reflecting the narrow therapeutic index and toxicity management requirements of panobinostat.[1]

The label includes warnings and precautions involving:

• Severe or fatal cardiac ischemic events, arrhythmias, and electrocardiogram changes
• Severe diarrhea and other gastrointestinal toxicity
• Thrombocytopenia, anemia, and neutropenia
• Hepatotoxicity
• Tumor lysis syndrome
• Hemorrhage
• Infections
• Embryo-fetal toxicity
• Drug interactions involving CYP3A metabolism

These risks affect excipient commercialization. A reformulation cannot be positioned solely as a manufacturing substitute if it materially changes absorption or peak exposure. Any formulation intended to improve tolerability would require exposure-response and clinical support.

Farydak is not a biologic, so biosimilar regulation does not apply. The relevant competition is from generic panobinostat products, other multiple-myeloma regimens, and newer agents that may displace panobinostat from treatment algorithms.

How strong is the commercial opportunity for Farydak excipients?

The opportunity is niche but technically credible. Panobinostat is used in a heavily pretreated multiple-myeloma population, and the product is administered with other agents. That limits the absolute volume opportunity for a conventional generic excipient package.

The strongest commercial targets are:

Excipient suppliers

Suppliers can pursue co-processed filler-binders, low-moisture excipients, capsule-shell alternatives, and manufacturing aids optimized for low-dose oncology APIs. The value proposition should focus on content uniformity, dissolution, process yield, and stability rather than generic claims of improved patient outcomes.

Generic manufacturers

A lactose-free or gelatin-free capsule can create a modest point of differentiation in a specialty market. The most efficient strategy is to develop the differentiated composition within an ANDA-compatible immediate-release product rather than begin with a clinically intensive modified-release program.

505(b)(2) developers

A controlled-release or tolerability-oriented product has greater pricing potential but must overcome clinical, regulatory, and patent hurdles. The opportunity depends on demonstrating a clear benefit over the reference capsule, not merely changing inactive ingredients.

Contract development and manufacturing organizations

CDMOs with high-containment handling, low-dose blend expertise, and capsule-filling capability can compete for development and commercial supply contracts. Panobinostat requires disciplined containment and cleaning validation because of its pharmacologic potency and oncology use.

How does Farydak compare with competing multiple-myeloma products?

Farydak competes with proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and newer oral therapies. Its oral capsule format is operationally convenient, but its use with bortezomib and dexamethasone creates a multi-drug regimen and increases monitoring requirements.

Compared with large-volume oral oncology products, Farydak has a smaller addressable market. Compared with biologics, it has simpler manufacturing and storage requirements. Compared with generic small molecules, it has greater toxicity-management complexity and a more specialized prescriber base.

That competitive profile favors a low-cost, supply-reliable generic over a high-priced excipient-only reformulation unless the latter demonstrates a clinically relevant tolerability or adherence benefit.

Key Takeaways

• Farydak is an immediate-release panobinostat capsule in 10 mg, 15 mg, and 20 mg strengths.
• The disclosed excipient system is conventional and includes lactose monohydrate, pregelatinized starch, talc, and magnesium stearate.
• Lactose-free and gelatin-free versions are the most practical differentiation strategies.
• Low-dose content uniformity and powder-flow control are important manufacturing opportunities.
• Modified-release, sprinkle, and liquid products have greater potential value but require higher regulatory and clinical investment.
• Farydak is a small specialty oncology market, so excipient differentiation must be tied to measurable manufacturing, supply, or patient-use benefits.
• Generic entry depends on current Orange Book listings, Paragraph IV activity, litigation, settlement agreements, and the remaining commercial value of the reference product.
• Biosimilar competition does not apply because panobinostat is a small-molecule drug.

FAQs About Farydak Excipient and Generic Opportunities

Can lactose be removed from a Farydak generic?

Yes. An ANDA applicant can use a different inactive-ingredient system if the finished product satisfies pharmaceutical equivalence, bioequivalence, dissolution, stability, and quality requirements.

Is a gelatin-free Farydak capsule commercially viable?

Yes, but the opportunity is likely niche. A hypromellose shell could support vegetarian, halal, kosher, and non-animal product positioning, subject to stability and shell-performance testing.

Could a modified-release panobinostat product reduce toxicity?

It could be developed to test that objective, but the product would require evidence that altered pharmacokinetics improve tolerability without reducing efficacy. The development burden would be substantially higher than for a conventional generic capsule.

Does Farydak have biosimilar competition?

No. Farydak contains the small-molecule active ingredient panobinostat. Competition would come from generic or reformulated panobinostat products, not biosimilars.

What is the most attractive excipient opportunity in Farydak?

A lactose-free, immediate-release capsule supported by robust low-dose content uniformity and a reliable manufacturing process offers the best balance of technical feasibility, regulatory efficiency, and commercial differentiation.

References

1. Novartis Pharmaceuticals Corporation. (2024). Farydak (panobinostat) capsules, prescribing information. U.S. Food and Drug Administration.
2. U.S. Food and Drug Administration. (2015, February 23). FDA approves Farydak for patients with multiple myeloma.
3. U.S. Food and Drug Administration. (2020). Farydak: Approval history and regulatory information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.